Journal of Internal Medicine 1995; **237**: 607–610

Author Index

Aarbakke J *see* Stoa-Birketvedt *et al.*
Aarsland T *see* Grundt *et al.*
Aberg H *see* Tomson *et al.*
Abilgaard U *see* Dahl *et al.*
Abrahamsson H. Gastrointestinal motility disorders in patients with diabetes mellitus, 403
Agewall S, Fagerberg B, Attvall S, Ljungman S, Urbanavicius V, Tengborn L, Wikstrand J, on behalf of the Risk Factor Intervention Study Group. Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men, 195
Agewall S, *see also* Johannesson *et al.*
Agger AO *see* Milman *et al.*
Ahlner J *see* Leppert *et al.*
Ahrén B *see* Larsson *et al.*
Akerblom A *see* Olsson *et al.*
Al-Momen AK. Diminished vitamin B_{12} levels in patients with severe sickle cell disease, 551
Andersson A *see* Landgren *et al.*
Andersson C, Thunell S, Floderus Y, Forsell C, Lundin G, Anvret M, Lannfelt L, Wetterberg L, Lithner F. Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods, 301
Andersson DEH *see* Wikner *et al.*
Antila K *see* Luutonen *et al.*
Anvret M *see* Andersson *et al.*
Arnon R *see* Zimmerman *et al.*
Arstila M *see* Salomaa *et al.*
Asplund K. Stroke therapy, time for a clinical breakthrough (*Introduction*), 73
Attvall S *see* Agewall *et al.*
Axdorph U, Nilsson BI, Nilsson BR, Björkholm M. Leucocyte doubling time is a useful predictor of progression-free survival in chronic lymphocytic leukaemia, 205
Axelsen M, Eliasson B, Joheim E, Lenner RA, Taskinen M-R, Smith U. Lipid intolerance in smokers, 449

De Backer W *see* Janson *et al.*
Baksaas I *see* Grundt *et al.*
Barnwell SL *see* Higashida *et al.*
Bath PMW *see* Blann *et al.*
Belcher JD *see* Salonen *et al.*
Bencsik ZS, Szabolcs I, Góth M, Vörös A, Kaszas I, Gönczi J, Kovács L, Dohán O, Szilágyi G. Incidentally detected adrenal tumours (incidentalomas): histological heterogeneity and differentiated therapeutic approach, 585
Bender R *see* Mühlhauser *et al.*
Bengtsson C *see* Persson *et al.*
Benker G *see* Wejda *et al.*
Berg KJ *see* Holdaas *et al.*
Berger M *see* Mühlhauser *et al.*
Berglund G *see* Larsson *et al.*
Beshyah SA, Shahi M, Foale R, Johnston DG. Cardiovascular effects of prolonged growth hormone replacement in adults, 35
Best JD *see* Jenkins *et al.*
Björkholm M *see* Axdorph *et al.*
Björnsson E *see* Janson *et al.*
Blann AD, Jackson P, Bath PMW, Watts GF. von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet, 557
Bleijenberg GIJS *see* Swanink *et al.*
Boeve WJ *see* Hoogenberg *et al.*
Boman G *see* Janson *et al.*
Bott U *see* Mülhauser *et al.*
Böttiger LE. Integrative biology (physiology) – a necessity!, 345
Boysen G, Overgaard K. Thrombolysis in acute ischaemic stroke – how far from a clinical breakthrough?, 95
Brattström L *see* Landgren *et al.*
Brenner MK. Human somatic gene therapy: progress and problems, 229
Brooks CH *see* Schneider *et al.*
Brzezinska A *see* Slowinska-Srzednicka *et al.*
Bystad L *see* Holdaas *et al.*

Chotkowska E *see* Slowinska-Srzednicka *et al.*
Compston A. Brain repair, 127
ver Coulen JHMM *see* Swanink *et al.*

Dahl T, Abilgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?, 323
Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism, 221
Deckert T *see* Yokoyama *et al.*
Denison H *see* Wallerstedt *et al.*
Dohán O *see* Bencsik *et al.*
Dowd CF *see* Higashida *et al.*
van den Dungen JJAM *see* Hoogenberg *et al.*

Eastell R, on behalf of a UK Consensus Group Meeting on Osteoporosis. Management of corticosteroid-induced osteoporosis, 439
Eliasson B *see* Axelsen *et al.*
Ellis SJ. Peer review and conflicts of interest, 219
Eriksson H. Heart failure: a growing public health problem, 135
Eriksson P *see* Mooe *et al.*
Eriksson S, Janciauskiene S, Merlini G. The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils, 143
Ernst E. Haematocrit and cardiovascular risk, 527
van Essen LH *see* Hoogenberg *et al.*
Evangelopoulou C *see* Papapostolou *et al.*

Fagerberg B *see* Agewall *et al.*; Johannesson *et al.*
Fauchald P *see* Holdaas *et al.*
Fennis JFM *see* Swanink *et al.*

© 1995 Blackwell Science Ltd

Fleming C *see* Simmons *et al.*
Floderus Y *see* Andersson *et al.*
Florholmen J *see* Stoa-Birketvedt *et al.*
Foale R *see* Beshya *et al.*
Forsell C *see* Andersson *et al.*
Freese R *see* Mutanen *et al.*

Galama JMD *see* Swanink *et al.*
Gardlund B *see* Günther *et al.*
Gatland BA *see* Simmons *et al.*
Gislason T *see* Janson *et al.*
Glass II WF *see* Schneider *et al.*
Gönczi J *see* Bencsik *et al.*
Góth M *see* Bencsik *et al.*
Grande T *see* Grundt *et al.*
Graudal N *see* Milman *et al.*
Grotta J. Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy, 89
Grundt H, Nilsen DWT, Hetland Ø, Aarsland T, Baksaas I, Grande T, Woie L. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia, 249
Günther G, Gardlund B, Hast R, Kimby E, Nordin M, Wretlind B. Endotoxaemia and inflammatory mediators in febrile patients with haematological disease, 27
Gyntelberg F, Hein HO, Suadicani P, Sørensen H. Coffee consumption and risk of ischaemic heart disease – a settled issue?, 55

Halbach VV *see* Higashida *et al.*
Haller C, Salbach P, Katus H, Kübler W. Refractory oedema in congestive heart failure: a contributory role of loop diuretics?, 211
Hanseen LE *see* Jacobsen *et al.*
Hansson G *see* Kaczynski *et al.*
Hartford M *see* Johannesson *et al.*
Hartmann A *see* Holdaas *et al.*
Hassi J *see* Luoma *et al.*
Hast R *see* Günther *et al.*
Hedner T *see* Johannesson *et al.*
Hein HO *see* Gyntelberg *et al.*
Helin H *see* Wirta *et al.*
Hellström PM. Motility of small intestine: a case for pattern recognition, 391
Hellström PM, Nilsson I, Svenberg T. Role of bile in regulation of gut motility, 395
Hellström PM, *see also* Wisén *et al.*
Hetland Ø *see* Grundt *et al.*
Hetta J *see* Janson *et al.*
Hieshima GB *see* Higashida *et al.*
Higashida RT, Tsai FY, Halbach VV, Barnwell SL, Dowd CF, Hieshima GB. Interventional neurovascular techniques in the treatment of stroke – state-of-the-art therapy, 105
Hintze G *see* Wejda *et al.*
Holdaas H, Hartmann A, Berg KJ, Langberg H, Bystad L, Fauchald P. Contrasting effects of angiotensin converting inhibitor and alpha-1-antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy, 63
Holm S. The medical hierarchy and its perceived influence on technical and ethical decisions, 487
Hoogenberg K, van Essen LH, van den Dungen JJAM, Limberg AJ, Boeve WJ, Kleibeuker JH. Chronic mesenteric ischaemia: diagnostic challenges and treatment options, 293
Huikuri HV. Heart rate variability in coronary artery disease, 349
Hultberg B *see* Landgren *et al.*
Husebye E. Gastrointestinal motility disorders and bacterial overgrowth, 419

Israelsson B *see* Landgren *et al.*

Jackson P *see* Blann *et al.*
Jacobs DR Jr *see* Salonen *et al.*
Jacobsen MB, Hanseen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial, 269
Janciauskiene S *see* Eriksson *et al.*
Janson C, Gislason T, De Backer W, Planschke P, Björnsson E, Hetta J, Kristbjarnson H, Vermeire P, Boman G. Daytime sleepiness, snoring and gastro-oesophageal reflux amongst young adults in three European countries, 277
Jenkins AJ, Best JD. The role of lipoprotein(a) in the vascular complications of diabetes mellitus, 359
Jensen JS *see* Yokoyama *et al.*
Jensen T *see* Yokoyama *et al.*
Jeske W *see* Slowinska-Srzednicka *et al.*
Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple–risk-factor intervention programme in treated hypertensive men, 19
Johannesson M, *see also* Tomson *et al.*
Joheim E *see* Axelsen *et al.*
Johnston DG *see* Beshya *et al.*
Jönsson B. Cost-effectiveness: a new criterion for selecting therapy, 1
Jörgens V *see* Mühlhauser *et al.*

Kaczynski J, Hansson G, Thunell S, Wetterberg L, Wallerstedt S. Erythrocyte porphobilinogen deaminase activity and primary liver cancer, 309
Karp K *see* Mooe *et al.*
Kaszas I *see* Bencsik *et al.*
Katan MB *see* Mensink *et al.*
Katschinski B *see* Wejda *et al.*
Katus H *see* Haller *et al.*
Kimby E *see* Günther *et al.*
Kleefield J *see* Papapostolou *et al.*
Kleibeuker JH *see* Hoogenberg *et al.*
Koenig KG *see* Schneider *et al.*
Koivula T *see* Wirta *et al.*
Kontula K *see* Vuorio *et al.*
Korpela H *see* Salonen *et al.*
Kovács L *see* Bencsik *et al.*
Kristbjarnson H *see* Janson *et al.*
Krusius T *see* Mutanen *et al.*
Kübler W *see* Haller *et al.*
Kuulasmaa K *see* Salomaa *et al.*

Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homocysteine in acute myocardial

infarction: homocysteine-lowering effect of folic acid, 381
Langberg H *see* Holdaas *et al.*
Lannfelt L *see* Andersson *et al.*
Larsson H, Ahrén B, Lindgärde F, Berglund G. Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women, 537
Larsson O *see* Olsson *et al.*
Leakehe L *see* Simmons *et al.*
Lebbink WJ *see* Mensink *et al.*
Lenner RA *see* Axelsen *et al.*
Leppert J, Ringqvist A, Ahlner J, Myrdal U, Sörensen S, Ringqvist I. Cold exposure increases cyclic guanosine monophosphate in healthy women but not in women with Raynaud's phenomenon, 493
Limberg AJ *see* Hoogenberg *et al.*
Lindgärde F *see* Larsson *et al.*
Lindgren A *see* Landgren *et al.*
Lindström K *see* Persson *et al.*
Lingfors H *see* Persson *et al.*
Lithner F *see* Andersson *et al.*
Ljungman S *see* Agewall *et al.*
Lobbezoo IE *see* Mensink *et al.*
Lundin G *see* Andersson *et al.*
Luoma PV, Näyhä S, Sikkilä K, Hassi J. High serum alpha-tocopherol, albumin, selenium and cholesterol, and low mortality from coronary heart disease in northern Finland, 49
Luutonen S, Neuvonen P, Ruskoaho H, Räihä I, Rajala T, Antila K, Sourander L. The role of potassium in postural hypotension: electrolytes and neurohumoral factors in elderly hypertensive patients using diuretics, 375

Malczewska B *see* Slowinska-Srzednicka *et al.*
Mantzoros CS *see* Papapostolou *et al.*
Marsell R *see* Olsson *et al.*
van der Meer *see* Swanink *et al.*
Mensink RP, Lebbink WJ, Lobbezoo IE, Weusten-Van der Wouw MPME, Zock PL, Katan MB. Diterpene composition of oils from Arabica and Robusta coffee beans and their effects on serum lipids in man, 543
Merlini G *see* Eriksson *et al.*
Meroz Y *see* Zimmerman *et al.*
Miettinen H *see* Salomaa *et al.*
Milman N, Graudal N, Agger AO. Iron status markers during pregnancy: no relationship between levels at the beginning of the second trimester, prior to delivery and post partum, 261
Møller L *see* Nilsson *et al.*
Mooe T, Teien D, Karp K, Eriksson P. Left ventricular thrombosis after anterior myocardial infarction with and without thrombolytic treatment, 563
Morise T, Takeuchi Y, Takeda R. Rapid detection and prevalence of the variants of the angiotensinogen gene in patients with essential hypertension, 175
Moses AC *see* Papapostolou *et al.*
Mühlhauser I, Bott U, Overmann H, Wagener W, Bender R, Jörgens V, Berger M. Liberalized diet in patients with type 1 diabetes, 591
Mustaniemi H *see* Salomaa *et al.*
Mustonen J *see* Wirta *et al.*
Mutanen M, Krusius T, Räsänen L, Greese R, Vahtera E, Viikari JA. Habitual diet, platelet function, fibrinogen and factor VII coagulant activity in young Finns, 577
Myrdal U *see* Leppert *et al.*

Näyhä S *see* Luoma *et al.*
Neuvonen P *see* Luutonen *et al.*
Nilsen DWT *see* Grundt *et al.*
Nilsson BI *see* Axdorph *et al.*
Nilsson BR *see* Axdorph *et al.*
Nilsson I *see* Hellström *et al.*
Nilsson PM, Møller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males, 479
Nordin M *see* Günther *et al.*
Nyyssönen K *see* Salonen *et al.*

Ojala J-P *see* Vuorio *et al.*
Oksa H *see* Wirta *et al.*
Olander B *see* Olsson *et al.*
Olbricht Th *see* Wejda *et al.*
Olsson KS, Marsell R, Ritter B, Olander B, Akerblom A, Östergard H, Larsson O. Iron deficiency and iron overload in Swedish male adolescents, 187
Orrenius S. Apoptosis: molecular mechanisms and implications for human disease, 529
Ossowski M *see* Slowinska-Srzednicka *et al.*
Östergard H *see* Olsson *et al.*
Overgaard K *see* Boysen *et al.*
Overmann H *see* Mühlhauser *et al.*

Palomäki P *see* Salomaa *et al.*
Papapostolou C, Mantzoros CS, Evangelopoulou C, Moses AC, Kleefield J. Imaging of the sella in the syndrome of inappropriate secretion of antidiuretic hormone, 181
Pasternack A *see* Wirta *et al.*
Persson L-G, Lindström K, Lingfors H, Bengtsson C. Interrelation between risk factors for cardiovascular disease in men aged 33–42. A study from Habo in Skaraborg County, Sweden, 457
Planschke P *see* Janson *et al.*
Porkkala E *see* Salonen *et al.*

Räihä I *see* Luutonen *et al.*
Rajala T *see* Luutonen *et al.*
Räsänen L *see* Mutanen *et al.*
Ribacke M. Treatment preferences, return visit planning and factors affecting hypertension practice amongst general practitioners and internal medicine specialists (The general practitioner hypertension practice study), 473
Ringqvist A *see* Leppert *et al.*
Ringqvist I *see* Leppert *et al.*
Ritter B *see* Olsson *et al.*
Röjdmark S *see* Wikner *et al.*
Rössner S *see* Wolk *et al.*
Rüs P. The future internist: how do we conceive of him or her as a student?, 125
Ruskoaho H *see* Luutonen *et al.*

Sadowski Z *see* Slowinska-Srzednicka *et al.*
Salbach P *see* Haller *et al.*
Salomaa V, Miettinen H, Palomäki P, Arstila M, Mustaniemi H,

Kuulasmaa K, Tuomilehto J, for the FINMONICA AMI Register Study Group. Diagnostic features of acute myocardial infarction – changes over time from 1983 to 1990: results from the FINMONICA EMI register study, 151

Salonen JT, Korpela H, Nyyssönen K, Porkkala E, Tuomainen T-P, Belcher JD, Jacobs DR Jr, Salonen R. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers, 161

Salonen R *see* Salonen *et al.*

Sandset PM *see* Dahl *et al.*

Sandström J *see* Wallerstedt *et al.*

Sarna S *see* Vuorio *et al.*

Schneider BF, Glass II WF, Brooks CH, Koenig KG. Membranous glomerulonephritis associated with testicular seminoma, 599

Shahi M *see* Beshya *et al.*

Siguenciz A *see* Zimmerman *et al.*

Sikkilä K *see* Luoma *et al.*

Simmons D, Gatland BA, Leakehe L, Fleming C. Frequency of diabetes in family members of probands with non-insulin-dependent diabetes mellitus, 315

Slowinska-Srzednicka J, Malczewska B, Srzednicki M, Chotkowsk- E, Brzezinska A, Zgliczynski W, Ossowski M, Jeske W, Zgliczynski S, Sadowski Z. Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease, 465

Smith U. Smoking elicits the insulin resistance syndrome: new aspects of the harmful effect of smoking, 435

Smith U, *see also* Axelsen *et al.*

Solstad K *see* Nilsson *et al.*

Sørensen H *see* Gyntelberg *et al.*

Sörensen S *see* Leppert *et al.*

Sourander L *see* Luutonen *et al.*

Srzednicki M *see* Slowinska-Srzednicka *et al.*

Stoa-Birketvedt G, Thom E, Aarbakke J, Florholmen J. Body fat as a predictor of the antihypertensive effect of nifedipine, 169

Suadicani P *see* Gyntelberg *et al.*

Svenberg T *see* Hellström *et al.*

Swanink CMA, ver Coulen JHMM, Bleijenberg GIJS, Fennis JFM, Galama JMD, van der Meer JWM. Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group, 499

Szabolcs I *see* Bencsik *et al.*

Szilágyi G *see* Bencsik *et al.*

Takeda R *see* Morise T *et al.*

Takeuchi Y *see* Morise T *et al.*

Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies, 5

Taskinen M-R *see* Axelsen *et al.*

Teien D *see* Mooe *et al.*

Tengborn L *see* Agewall *et al.*

Thom E *see* Stoa-Birketvedt *et al.*

Thunell S *see* Andersson *et al.*; Kaczynski *et al.*

Tikkanen MJ *see* Vuorio *et al.*

Tomson Y, Johannesson M, Aberg H. The costs and effects of two different lipid intervention programmes in primary health care, 13

Tsai FY *see* Higashida *et al.*

Tsvang E *see* Zimmerman *et al.*

Tuomainen T-P *see* Salonen *et al.*

Tuomilehto J *see* Salomaa *et al.*

Turtola H *see* Vuorio *et al.*

Urbanavicius V *see* Agewall *et al.*

Vahtera E *see* Mutanen *et al.*

Vermeire P *see* Janson *et al.*

Viikari JA *see* Mutanen *et al.*

Vörös A *see* Bencsik *et al.*

Vuorio AF, Ojala J-P, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Heterozygous familial hypercholesterolaemia: influence of mutation type of LDL receptor gene and *Pvu*II polymorphism of normal allele on serum lipid levels and response to lovastatin treatment, 43

Wagener W *see* Mühlhauser *et al.*

Wallerstedt S, Denison H, Sandström J, Westin J. The prevalence of alcoholism and its relation to cause of hospitalization and long-term mortality in male somatic inpatients, 339

Wallerstedt S, *see also* Kaczynski *et al.*

Watts GF *see* Blann *et al.*

Wejda B, Hintze G, Katschinski B, Olbricht Th, Benker G. Hip fractures and the thyroid: a case–control study, 241

Werkö L. Analysis of the MRFIT screenees: a methodological study, 507

Westin J *see* Wallerstedt *et al.*

Wetterberg L *see* Andersson *et al.*; Kaczynski *et al.*; Wikner *et al.*

Weusten-Van der Wouw MPME *see* Mensink *et al.*

Wikner J, Andersson DEH, Wetterberg L, Röjdmark S. Impaired melatonin secretion in patients with Wernicke–Korsakoff syndrome, 571

Wikstrand J *see* Agewall *et al.*

Wirta O, Pasternack A, Mustonen J, Oksa H, Koivula T, Helin H. Albumin excretion rate and its relation to kidney disease in non-insulin-dependent diabetes mellitus, 367

Wisén O, Hellström PM. Gastrointestinal motility in obesity, 411

Woie L *see* Grundt *et al.*

Wolk A, Rössner S. Effects of smoking and physical activity on body weight: developments in Sweden between 1980 and, 1989, 287

Wretlind B *see* Günther *et al.*

Yokoyama H, Jensen JS, Jensen T, Deckert T. Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy, 519

Zgliczynski S *see* Slowinska-Srzednicka *et al.*

Zgliczynski W *see* Slowinska-Srzednicka *et al.*

Zimmerman J, Meroz Y, Arnon R, Tsvang E, Siguenciz A. Predictors of mortality in hospitalized patients with secondary upper gastrointestinal haemorrhage, 331

Zock PL *see* Mensink *et al.*

del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1 Drugs promoting cerebral blood flow, 79

Journal of Internal Medicine 1995; **237**: 611–614

Subject Index

Adrenal tumours (incidentalomas), 585
Albumin excretion
  elevation in IDDM, 519
  and kidney disease in NIDDM, 367
  insulin sensitivity and haemostatic factors, non-diabetic treated hypertensive men, 195
  selenium, cholesterol, α-tocopherol, in CHD, 49
Alcoholism
  hospitalization and long-term mortality, 339
  Wernicke–Korsakoff syndrome, impaired melatonin secretion, 571
Alpha-1-antitrypsin
  role in disaggregation of amyloid lambda fibrils, 143
Alpha-tocopherol
  albumin, selenium, and cholesterol, in CHD, 49
Amyloid lambda fibrils
  alpha-1-antitrypsin , role in disaggregation, 143
Angio-oedema
  and endometriosis, danazol therapy, 603
Angiotensin converting inhibitor
  and alpha-1-antagonists, effect on albuminuria in IDDM nephropathy, 63
Angiotensinogen gene
  in essential hypertension, 175
Animal models
  stroke and neuroprotective therapy, 89
Anticoagulant therapy
  cerebrovascular disease, benefits, 323
Antidiuretic hormone
  syndrome of inappropriate secretion, 181
Antihypertensives
  body fat and nifedipine, 169
Antioxidants
  lipoproteins, smoking and body iron stores, 161
Apoptosis
  molecular mechanisms, disease implications, 529
Atherogenesis
  n-3 fatty acids, blood pressure, insulin levels in combined hyperlipidaemia, 249
Atherosclerosis
  HDL lipoproteins, cholesteryl ester transfer protein, molecular genetic studies, 5
  von Willebrand factor, 432
Atrial natriuretic peptide and amyloidosis, 525

Bacterial overgrowth
  and gastrointestinal motility disorders, 419
Bile
  in regulation of gut motility, 395
Bleeding
  long-term anticoagulant therapy, 323
Blood glucose
  determination of prevalence of diabetes, 537
Blood pressure
  lipids, n-3 fatty acids and insulin levels in combined hyperlipidaemia, 249
Body weight
  smoking and physical activity effects, 287
Bone mineral density
  hip fractures, and the thyroid, 241
Brain imaging
  inappropriate secretion of ADH, 181
Brain repair, 127

Calcium entry-blockade
  fat as predictor of antihypertensive effects, 169
  stroke, 91
Cardiovascular disease
  economic evaluation, 19
  multiple–risk-factor intervention programme, cost-effectiveness, 19
  risk factors in men aged 33–42, 457
  and sleep, 215
Cardiovascular effects
  growth hormone replacement, 35
Cell death, 529
Cerebral blood flow, 79
Cerebrovascular disease *see* Stroke
Cholesterol
  in CHD, 49
  see also Hypercholesterolaemia
Cholesteryl ester transfer protein
  and high-density lipoproteins, genetic studies, 5
Chronic fatigue syndrome, 499
Cobalamin (vitamin B_{12})
  levels in patients with severe sickle cell disease, 551
Coeliac disease, 118
Coffee beans
  diterpene composition of oils, and serum lipids in man, 543
Coffee consumption
  risk of ischaemic heart disease, 55
Cold exposure
  cyclic guanosine monophosphate, and Raynaud's phenomenon, 493
Coronary artery disease
  heart rate variability, 349
  hyperinsulinaemia and levels of dehydroepiandrosterone sulfate in premenopausal women, 465
  MRFIT trial, 507
  results from the FINMONICA AMI register study, 151
  risk factors, 457, 527
  serum alpha-tocopherol, albumin, selenium and cholesterol, in CHD, 49
  von Willebrand factor, endothelial cell damage, and lipid-lowering diet, 557
Corticosteroid-induced osteoporosis, 439
Cost-effectiveness *see* Economic evaluation

Danazol
  endometriosis and angio-oedema, 603

© 1995 Blackwell Science Ltd

Dehydroepiandrosterone sulfate
and hyperinsulinaemia, in premenopausal women with CHD, 465
Diabetes mellitus
albuminuria in IDDM nephropathy, ACE inhibitors and alpha-1-antagonists, 63
diet, 591
fasting blood glucose in determination of prevalence, 537
gastrointestinal motility disorders, 403
lipoprotein(a) in vascular complications, 359
serum sialic acid elevation, 519
Diabetes mellitus, NIDDM
albumin excretion rate and kidney disease, 367
frequency in family members of probands, 315
Diet
diabetes mellitus, 591
factor VII, platelet function and fibrinogen, 577
lipid-lowering, endothelial cell damage, and von Willebrand factor, 557
Diuretics
refractory oedema in congestive heart failure, 211
role of potassium in postural hypotension, 375
Doppler
cardiovascular effects of growth hormone replacement, 35

Echocardiography
cardiovascular effects of growth hormone replacement, 35
Economic evaluation, 1, 13, 19
cardiovascular multiple–risk-factor intervention programme, 19
as criterion for selecting therapy, 1
lipid intervention programmes in primary health care, 13
EDTA chelation
peripheral vascular disease, 429
Endometriosis and angio-oedema
danazol therapy, 603
Endotoxaemia
inflammatory mediators in febrile patients with haematological disease, 27
Erythrocyte porphobilinogen deaminase activity
and primary liver cancer, 309

Factor V, gene mutation
inherited resistance to activated protein C, 221
Factor VII
platelet function and fibrinogen, 577
Fat, body fat as predictor of antihypertensive effect of nifedipine, 169
Fatty acids
blood pressure, insulin levels in combined hyperlipidaemia, 249
Fibrinogen
platelet function and factor VII activity, 577
FINMONICA AMI Register Study Group, AMI, 151
Folic acid
homocysteine-lowering effects, AMI, 381

Gastric ulcer
diagnosis and treatment options, 293
Gastro-oesophageal reflux
sleep habits, 277
Gastrointestinal haemorrhage, upper
predictors of mortality in hospitalized patients, 331
Gastrointestinal motility
in obesity, 411
Gastrointestinal motility disorders
and bacterial overgrowth, 419
in diabetes mellitus, 403
pattern recognition, 391
role of bile, 395
Gastrointestinal neuroendocrine tumours
octreotide clinical trial, 269
Gene therapy
somatic, progress and problems, 229
General practitioner hypertension practice study, 473
Glucose tolerance test
determination of prevalence of diabetes, 537
Gonadal function
and insulin levels, psychosocial stress, 479
Growth factors
brain repair, 127
Growth hormone replacement
cardiovascular effects in adults, 35
Guanosine monophosphate
cold exposure, and Raynaud's phenomenon, 493

Haematemesis
predictor of mortality in hospitalized patients, 331
Haematocrit
and cardiovascular risk, 527
Heart failure
congestive, and loop diuretics?, 211
as public health problem, 135
Heart rate
variability and coronary artery disease, 349
Hip fractures
and the thyroid, 241
Homocysteine
in acute myocardial infarction, effects of folic acid, 381
Hypercholesterolaemia
economic evaluation, 13
familial, mutation type of LDL receptor gene and *Pvu*II polymorphism of normal allele, effects on serum lipids, 43
von Willebrand factor, endothelial cell damage, and lipid-lowering diet, 557
see also Cholesterol
Hyperinsulinaemia
and levels of dehydroepiandrosterone sulfate, in premenopausal women with CHD, 465
and nesidioblastosis, 117
Hyperlipidaemia
lipids, insulin levels, and blood pressure, 249
in smokers, 449
Hypertension
cardiovascular multiple–risk-factor intervention programme, 19
essential, angiotensinogen gene, 175
general practitioner hypertension practice study, 473
microalbuminuria, insulin sensitivity and haemostatic factors, non-diabetic treated hypertensive men, 195
Hypotension, postural
role of potassium, in elderly hypertensive patients using diuretics, 375

Incidentalomas (adrenal tumours), 585
Inflammatory mediators
  febrile patients with haematological disease, 27
Insulin levels
  gonadal function, psychosocial stress, 479
Insulin resistance syndrome
  and smoking, 435, 449
  von Willebrand factor, 433
Insulin sensitivity
  albumin excretion, 195
  haemostatic factors in non-diabetic treated hypertensive men, 195
Internist
  as a student, 125
Iron
  deficiency and overload, 187
  markers during pregnancy, 261
  stores, blood letting and oxidation resistance of serum lipoproteinsin smokers, 161
Ischaemic heart disease
  and coffee consumption, 55

Kidney disease
  albumin excretion rate in NIDDM, 367

Left ventricular thrombosis
  after AMI, with/without thrombolytic treatment, 563
Leucocyte doubling time
  predictor of progression-free survival, chronic lyphocytic leukaemia, 205
Lipid-lowering diet
  endothelial cell damage, decrease during long-term lipid-lowering diet, 557
Lipids
  and blood pressure, n-3 fatty acids, insulin levels in combined hyperlipidaemia, 249
  intervention programmes, cost-effectiveness in primary health care, 13
  intolerance, in smokers, 449
Lipoproteins
  HDL, cholesteryl ester transfer protein, molecular genetic studies, 5
  LDLR gene, and *Pvu*II polymorphism, response to lovastatin treatment, 43
  lipoprotein(a), vascular complications of diabetes mellitus, 359
  smoking and body iron stores, 161
Lovastatin
  treatment of familial hypercholesterolaemia, mutation type of LDL receptor gene and *Pvu*II polymorphism of normal allele, 43
Lymphocytic leukaemia
  leucocyte doubling time, 205

Medical ethics, 487
Medical hierarchy
  technical and ethical decisions, 487
Melatonin
  secretion in Wernicke–Korsakoff syndrome, 571
Membranous glomerulonephritis
  and testicular seminoma, 599
Mesenteric ischaemia, chronic
  diagnosis and treatment options, 293
MONICA Project, 151
MRFIT trial
  methodological study, 507
MRI
  inappropriate secretion of ADH (SIADH), 181
Mutation analysis
  acute intermittent porphyria, 301
Myocardial infarction
  homocysteine-lowering effects of folic acid, 381
  left ventricular thrombosis after, with/without thrombolytic treatment, 563
  results from the FINMONICA EMI register study, 151

Nesidioblastosis
  and hyperinsulinaemia, 117
Neurodegeneration
  brain repair, 127
Neuroendocrine tumours
  GI tract, octreotide clinical trial, 269
Nifedipine
  fat as predictor of antihypertensive effects, 169

Obesity
  gastrointestinal motility, 411
Octreotide
  gastrointestinal neuroendocrine tumours, clinical trial, 269
Oral glucose tolerance test
  determination of prevalence of diabetes, 537
Osteoporosis
  corticosteroid-induced osteoporosis, 439
  hip fractures, and the thyroid, 241

Paraneoplastic syndrome
  and testicular seminoma, 599
Peer review
  conflicts of interest, 219
Peripheral vascular disease
  EDTA chelation, 429
Physical activity
  and smoking, body weight, 287
Platelet function, fibrinogen and factor VII activity, 577
Porphobilinogen deaminase activity
  and primary liver cancer, 309
Porphyria, acute
  diagnosis: an evaluation of mutation analysis and biochemical methods, 301
Postviral fatigue syndrome, 499
Potassium
  role in postural hypotension, 375
Pregnancy
  iron levels, 261
Protein C
  factor V gene mutation, and venous thromboembolism, 221
Psoriasis, 118

Raynaud's phenomenon
  cold exposure and cGMP, 493
Risk Factor Intervention Study Group, 195

Selenium
  in CHD, 49

Sella
  imaging, syndrome of inappropriate secretion of ADH, 181
SIADH (syndrome of inappropriate secretion of antidiuretic hormone), 181
Sialic acid
  elevation in IDDM, 519
Sickle cell disease
  diminished vitamin B_{12} levels, 551
Sleep
  and cardiac diseases, 215
  snoring and gastro-oesophageal reflux, 277
Smoking
  and insulin resistance syndrome, 435
  lipid intolerance in smokers, 449
  lowering of iron stores, trial, 161
  and physical activity, body weight, 287
Somatic gene therapy
  progress and problems, 229
Stress
  psychosocial, effect on gonadal function and insulin levels, 479
Stroke
  risk, and haematocrit, 527
Stroke therapy
  introduction, 73
  anticoagulant therapy, 323
  cerebral blood flow promotion, 79
  interventional neurovascular techniques, 105
  neuroprotective therapy, animal models, 89
  thrombolysis therapy, 95
Student internists, 125

T-cell depletion
  apoptosis, 529
Takayasu's arteritis, 217
Testicular seminoma
  and membranous glomerulonephritis, 599
Thrombolysis
  in acute ischaemic stroke, 95
  left ventricular thrombosis after AMI, 563
Thyroid
  and hip fractures, 241

Venous thromboembolism, 221
Vitamin B_{12}
  levels in patients with severe sickle cell disease, 551
von Willebrand factor
  and atherosclerosis, 432
  endothelial cell damage, and lipid-lowering diet, 557
  insulin resistance syndrome, 433

Wernicke–Korsakoff syndrome
  impaired melatonin secretion, 571